ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

How Tacrolimus Variability Affects Donor Specific Antibodies, Rejection and Outcome After Kidney Transplantation.

S. Papachristos, A. John Velvet, A. Summers, A. Tavakoli, R. Dhanda, R. Pararajasingam, B. Forgacs.

Manchester Transplantation Unit, Manchester Royal Infirmary Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom.

Meeting: 2016 American Transplant Congress

Abstract number: B116

Keywords: FK506, Kidney transplantation, Outcome, Rejection

Session Information

Session Name: Poster Session B: Drug Minimization

Session Type: Poster Session

Date: Sunday, June 12, 2016

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Purpose:To investigate the effect of tacrolimus(tac) variability on the development of Donor Specific Antibodies(DSA),rejection and outcome in relation to Age, Gender, Ethnicity and Body Mass Index(BMI) in a single high volume center. Methods:The study included 209 kidney transplant recipients aged between 17 and 79 years, from Jan 2013 to Dec 2013. Mean, Standard Deviation(SD) and Coefficient Variability(CV) of 5 consecutive tac trough measurements after first 3 months of transplant were calculated. A tac variability calculator was utilized, using the formula “CV=(SD/Mean)x100”. CV>20% was considered significant. Primary end points of rejection episodes and graft outcome at 1 year were recorded. Results:25.4%(n=53) of the cohort achieved the desired average tac levels(4-7ng/ml) at the end of 3 months post transplant. Only 62%(n=130) achieved tac CV≤20%, of which 2.3%(n=3) developed a rejection episode. 38%(n=79) had a tac CV>20%, of which 5.13%(n=4) developed a rejection episode(p=0.43). DSA followed same pattern, with 3.4% developing DSA from the tac CV>20% group and only 2.4% DSA from the Tac≤20% group. There were no significant correlations of tac CV with age and BMI (Pearson's correlation). Gender and ethnicity did not associate with tac CV(Chi-square). Mean tac levels were highest in the White recipient group(8.7ng/ml) and lowest on the Black group(4.4ng/ml)(p=0.006 student t test). At 1 year post transplant, 98%(n=205) had a functioning graft. Of the failed ones, all of them had tac CV>20%, with 1 death(no rejections), and 2 graft failures due to rejection. When comparing mean tac levels with rejection, there was 2.6% rejections in the high mean tac group while in the group with mean tac levels within the desired range, rejection rate was 4%. Similarly, development of DSA was only 2.6% in the high mean tac group and 4% in the normal range mean tac group.Conclusions: 38% of our cohort presented high Tac variability. As the episodes for rejection and DSA were low, we found no significant correlation between tac CV, rejection and DSA, even though there was a trend for higher rejection and DSA in the tac CV>20% group. We had 2 graft losses due to rejection, both from the high tac CV group. Interestingly, there was no association between tac CV and age, gender, BMI or ethnicity.

CITATION INFORMATION: Papachristos S, John Velvet A, Summers A, Tavakoli A, Dhanda R, Pararajasingam R, Forgacs B. How Tacrolimus Variability Affects Donor Specific Antibodies, Rejection and Outcome After Kidney Transplantation. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Papachristos S, Velvet AJohn, Summers A, Tavakoli A, Dhanda R, Pararajasingam R, Forgacs B. How Tacrolimus Variability Affects Donor Specific Antibodies, Rejection and Outcome After Kidney Transplantation. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/how-tacrolimus-variability-affects-donor-specific-antibodies-rejection-and-outcome-after-kidney-transplantation/. Accessed May 31, 2025.

« Back to 2016 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences